MIT professor slams Harvard’s stem cell bid
An MIT biotechnologist has pleaded with Harvard University not to pursue plans to do therapeutic cloning. Associate Professor James Sherley wrote in the Boston Globe that “adult stem cell research is predicted to beat the pants off human therapeutic cloning research when it come to yielding significant advances in cell medicine.” Given the unresolved debate over whether the research is ethical, he argues, “no reviewing body could, in good faith, approve it”. Prof Sherley also argued that the moral argument for therapeutic cloning was self-contradictory. At least reproductive cloning (which he staunchly opposes) creates life, while therapeutic cloning destroys it.
- Prescribe morning-after pills to young teenagers, say US pediatric group - November 30, 2012
- Bahrain sentences protest docs to prison - November 28, 2012
- Terry Pratchett assisted suicide documentary wins International Emmy - November 27, 2012
More Stories
A painful debate: shrinking the carbon footprint of anaesthetics
If there is any profession which seems remote from the Sturm und Drang of climate change, it must be anaesthetists....
Some patients recall death experiences after heart attacks
In an article in the journal Resuscitation, some survivors of cardiac arrest have described lucid death experiences that occurred while...
Queensland widower dies after taking assisted suicide drugs ordered by his wife
“Move along, please. Nothing to see here.” This was more or less the reaction of supporters of “voluntary assisted dying”...
Australian first: nurse donates organs after euthanasia
A Victorian woman has become the first Australian to combine death by euthanasia with organ donation. Ballarat nurse Marlene Bevern,...
Canadian study hints at crushing institutional conscience objections to ‘assisted dying’
Supporters of “voluntary assisted dying” fought hard to achieve legalisation in various jurisdictions around the world. After legalisation, however, battles...
Hope, hype and xenotransplantation
On January 7, 2022 David Bennett, a 57-year-old with terminal heart disease, made history as the first person to receive...